GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (OTCPK:ACHKF) » Definitions » Net Income Including Noncontrolling Interests

Achiko AG (Achiko AG) Net Income Including Noncontrolling Interests : $-6.86 Mil (TTM As of Jun. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Achiko AG Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Achiko AG's Net Income Including Noncontrolling Interests for the six months ended in Jun. 2022 was $-2.50 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2022 was $-6.86 Mil.

Achiko AG Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Achiko AG's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achiko AG Net Income Including Noncontrolling Interests Chart

Achiko AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Net Income Including Noncontrolling Interests
- -7.32 -14.07 -9.32

Achiko AG Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial -5.04 -9.03 -4.96 -4.36 -2.50

Achiko AG Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-6.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achiko AG Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Achiko AG's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Achiko AG (Achiko AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (OTCPK:ACHKF) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
SZSE:300869 SZSE:300314 SZSE:300246 SZSE:300633 SZSE:301033 SZSE:300813 SHSE:688016 SZSE:300206 SZSE:301235 SHSE:688389 CERN VEEV TSE:2413 CHNG DOCS NUTX RCM TDOC TXG HQY
Traded in Other Exchanges
N/A
Address
Tessinerplatz 7, Zurich, CHE, CH-8002
Website
https://www.achiko.com
Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.